DeepMed Research

PARATEK PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1996-01-01

Employees: 268

Market Cap: -

Website: http://www.paratekpharma.com

Clinical Trials

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Phase 1

Recruiting

Conditions: Bacterial Infections

Interventions: Drug: Omadacycline Injection [Nuzyra]
Drug: Omadacycline Oral Tablet

First Posted Date: 2022-02-01

Last Posted Date: 2024-08-22

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 40

Registration Number: NCT05217537

Locations: 🇺🇸
Site 109, Little Rock, Arkansas, United States
🇺🇸
Site 108, Houston, Texas, United States
🇺🇸
Site 107, Orange, California, United States

and more 6 locations

Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Phase 2

Completed

Conditions: Mycobacterium Infections, Nontuberculous
Nontuberculous Mycobacterial Pulmonary Infection
Mycobacterium Abscessus Infection
Nontuberculous Mycobacterial Lung Disease

Interventions: Drug: Placebo
Drug: Omadacycline Oral Tablet

First Posted Date: 2021-06-10

Last Posted Date: 2024-10-03

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 66

Registration Number: NCT04922554

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
St. Francis Medical Institute, Clearwater, Florida, United States

and more 14 locations

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

Phase 3

Completed

Conditions: Community-acquired Pneumonia
Bacterial Pneumonia

Interventions: Drug: Moxifloxacin
Drug: Omadacycline

First Posted Date: 2021-03-03

Last Posted Date: 2025-04-09

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 670

Registration Number: NCT04779242

Locations: 🇭🇺
Site 803, Debrecen, Hungary
🇧🇬
Site 212, Vidin, Bulgaria
🇧🇬
Site 206, Ruse, Bulgaria

and more 52 locations

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

Phase 1

Completed

Conditions: Community-acquired Pneumonia

Interventions: Drug: Omadacycline

First Posted Date: 2019-11-12

Last Posted Date: 2021-11-03

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 18

Registration Number: NCT04160260

Locations: 🇺🇸
Site 106, Doral, Florida, United States
🇺🇸
Site 102, San Diego, California, United States
🇺🇸
Site 104, San Diego, California, United States

and more 10 locations

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

Phase 2

Completed

Conditions: Acute Pyelonephritis

Interventions: Drug: Omadacycline
Drug: Levofloxacin

First Posted Date: 2018-11-28

Last Posted Date: 2020-07-07

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 201

Registration Number: NCT03757234

Locations: 🇬🇪
Site 204, Tbilisi, Georgia
🇱🇻
Site 305, Rēzekne, Latvia
🇱🇻
Site 304, Liepāja, Latvia

and more 28 locations

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Phase 2

Completed

Conditions: Infectious Skin Disease
Bacterial Skin Disease

Interventions: Drug: PTK 0796
Drug: Linezolid

First Posted Date: 2018-10-23

Last Posted Date: 2020-10-12

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 234

Registration Number: NCT03716024

Locations: 🇺🇸
Paratek Recruiting Site, Wichita Falls, Texas, United States

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

Phase 2

Completed

Conditions: Cystitis
Uncomplicated Urinary Tract Infection

Interventions: Drug: Omadacycline tablets
Drug: Nitrofurantoin capsules

First Posted Date: 2018-02-07

Last Posted Date: 2020-06-09

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 225

Registration Number: NCT03425396

Locations: 🇺🇸
Site 101, La Mesa, California, United States
🇺🇸
Site 102, DeLand, Florida, United States
🇺🇸
Site 114, Aventura, Florida, United States

and more 20 locations

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Phase 3

Completed

Conditions: Bacterial Infections
Skin Structures and Soft Tissue Infections

Interventions: Drug: Omadacycline
Drug: Linezolid

First Posted Date: 2016-08-24

Last Posted Date: 2018-11-30

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 735

Registration Number: NCT02877927

Locations: 🇺🇸
Site 620, Birmingham, Alabama, United States
🇺🇸
Site 606, Buena Park, California, United States
🇺🇸
Site 604, Chula Vista, California, United States

and more 47 locations

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Phase 3

Completed

Conditions: Community-Acquired Infections
Bacterial Pneumonia

Interventions: Drug: Moxifloxacin
Drug: Omadacycline

First Posted Date: 2015-08-24

Last Posted Date: 2019-01-16

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 774

Registration Number: NCT02531438

Locations: 🇵🇪
Site 481, Lima, Peru
🇨🇿
Site 411, Praha 10, Czechia
🇧🇬
Site 303, Pernik, Bulgaria

and more 137 locations

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Phase 3

Completed

Conditions: Skin Structures and Soft Tissue Infections
Bacterial Infections

Interventions: Drug: Omadacycline
Drug: Linezolid

First Posted Date: 2015-03-04

Last Posted Date: 2019-03-21

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 655

Registration Number: NCT02378480

Locations: 🇺🇸
Site 256, Augusta, Georgia, United States
🇺🇸
Site 252, Santa Ana, California, United States
🇺🇸
Site 259, Miami, Florida, United States

and more 75 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy